Tags

Type your tag names separated by a space and hit enter

Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.
Pediatr Infect Dis J 2013; 32(3):278-83PI

Abstract

BACKGROUND

Effectiveness of the pentavalent rotavirus vaccine (RV5) after administration of the complete (3 dose) regimen has been demonstrated in a real-world setting. This study assessed the effectiveness of RV5 following partial completion of the 3-dose regimen.

METHODS

Using a large national health insurance claims database, 2 cohorts of infants (those who received RV5 and a concurrent group who received diphtheria-tetanus-acellular pertussis, but not RV5) were followed through the 2007 and 2008 rotavirus seasons (January 1 to May 31) to identify cases of rotavirus gastroenteritis and all-cause gastroenteritis resulting in medical care encounters. Vaccine effectiveness following the first and the second RV5 doses was estimated by quantifying reductions in hospitalizations, emergency department (ED) and physician office visits.

RESULTS

A first RV5 dose was received by 42,306 infants whereas 28,417 infants in the concurrent comparison group received a first diphtheria-tetanus-acellular pertussis dose; 43,704 infants received a second RV5 dose, and 31,810 infants received a second diphtheria-tetanus-acellular pertussis dose. One dose of RV5 was associated with 88% effectiveness against rotavirus gastroenteritis hospitalizations and ED visits and 44% effectiveness against all-cause gastroenteritis hospitalizations and ED visits. A 2-dose regimen of RV5 was associated with 94% effectiveness against rotavirus gastroenteritis hospitalizations and ED visits and 40% effectiveness against all-cause gastroenteritis hospitalizations and ED visits.

CONCLUSION

The RV5 vaccine exhibits effectiveness against rotavirus gastroenteritis even before completing the full 3-dose regimen. These results are of particular relevance when considering the benefits of a partially completed rotavirus vaccine series.

Authors+Show Affiliations

OptumInsight Epidemiology, Waltham, MA 02451, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23014356

Citation

Wang, Florence T., et al. "Effectiveness of an Incomplete RotaTeq (RV5) Vaccination Regimen in Preventing Rotavirus Gastroenteritis in the United States." The Pediatric Infectious Disease Journal, vol. 32, no. 3, 2013, pp. 278-83.
Wang FT, Mast TC, Glass RJ, et al. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States. Pediatr Infect Dis J. 2013;32(3):278-83.
Wang, F. T., Mast, T. C., Glass, R. J., Loughlin, J., & Seeger, J. D. (2013). Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States. The Pediatric Infectious Disease Journal, 32(3), pp. 278-83. doi:10.1097/INF.0b013e318275328f.
Wang FT, et al. Effectiveness of an Incomplete RotaTeq (RV5) Vaccination Regimen in Preventing Rotavirus Gastroenteritis in the United States. Pediatr Infect Dis J. 2013;32(3):278-83. PubMed PMID: 23014356.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States. AU - Wang,Florence T, AU - Mast,T Christopher, AU - Glass,Roberta J, AU - Loughlin,Jeanne, AU - Seeger,John D, PY - 2012/9/28/entrez PY - 2012/9/28/pubmed PY - 2013/9/21/medline SP - 278 EP - 83 JF - The Pediatric infectious disease journal JO - Pediatr. Infect. Dis. J. VL - 32 IS - 3 N2 - BACKGROUND: Effectiveness of the pentavalent rotavirus vaccine (RV5) after administration of the complete (3 dose) regimen has been demonstrated in a real-world setting. This study assessed the effectiveness of RV5 following partial completion of the 3-dose regimen. METHODS: Using a large national health insurance claims database, 2 cohorts of infants (those who received RV5 and a concurrent group who received diphtheria-tetanus-acellular pertussis, but not RV5) were followed through the 2007 and 2008 rotavirus seasons (January 1 to May 31) to identify cases of rotavirus gastroenteritis and all-cause gastroenteritis resulting in medical care encounters. Vaccine effectiveness following the first and the second RV5 doses was estimated by quantifying reductions in hospitalizations, emergency department (ED) and physician office visits. RESULTS: A first RV5 dose was received by 42,306 infants whereas 28,417 infants in the concurrent comparison group received a first diphtheria-tetanus-acellular pertussis dose; 43,704 infants received a second RV5 dose, and 31,810 infants received a second diphtheria-tetanus-acellular pertussis dose. One dose of RV5 was associated with 88% effectiveness against rotavirus gastroenteritis hospitalizations and ED visits and 44% effectiveness against all-cause gastroenteritis hospitalizations and ED visits. A 2-dose regimen of RV5 was associated with 94% effectiveness against rotavirus gastroenteritis hospitalizations and ED visits and 40% effectiveness against all-cause gastroenteritis hospitalizations and ED visits. CONCLUSION: The RV5 vaccine exhibits effectiveness against rotavirus gastroenteritis even before completing the full 3-dose regimen. These results are of particular relevance when considering the benefits of a partially completed rotavirus vaccine series. SN - 1532-0987 UR - https://www.unboundmedicine.com/medline/citation/23014356/Effectiveness_of_an_incomplete_RotaTeq__RV5__vaccination_regimen_in_preventing_rotavirus_gastroenteritis_in_the_United_States_ L2 - http://Insights.ovid.com/pubmed?pmid=23014356 DB - PRIME DP - Unbound Medicine ER -